120 related articles for article (PubMed ID: 11701896)
1. Parkinson's disease. Dopamine may sustain toxic protein.
Couzin J
Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
[No Abstract] [Full Text] [Related]
2. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Conway KA; Rochet JC; Bieganski RM; Lansbury PT
Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
Lotharius J; Brundin P
Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550
[No Abstract] [Full Text] [Related]
4. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease.
Li J; Zhu M; Manning-Bog AB; Di Monte DA; Fink AL
FASEB J; 2004 Jun; 18(9):962-4. PubMed ID: 15059976
[TBL] [Abstract][Full Text] [Related]
5. Toxic effects of dopamine metabolism in Parkinson's disease.
Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
[TBL] [Abstract][Full Text] [Related]
6. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
Ahlskog JE
Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
[TBL] [Abstract][Full Text] [Related]
7. [Free radicals and ailing proteins--the culprits behind Parkinson disease?].
Smith R; Lotharius J; Brundin P
Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
Kostrzewa RM; Kostrzewa JP; Brus R
Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
[TBL] [Abstract][Full Text] [Related]
9. Dopamine and Parkinson's disease: is the killer in the house?
Chesselet MF
Mol Psychiatry; 2003 Apr; 8(4):369-70. PubMed ID: 12740592
[No Abstract] [Full Text] [Related]
10. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire-Zeiss KA; Short DW; Federoff HJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
[TBL] [Abstract][Full Text] [Related]
11. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
12. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
15. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
16. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
17. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
Yokochi M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
[TBL] [Abstract][Full Text] [Related]
18. Lewy bodies in Parkinson's disease: protectors or perpetrators?
Harrower TP; Michell AW; Barker RA
Exp Neurol; 2005 Sep; 195(1):1-6. PubMed ID: 16023637
[No Abstract] [Full Text] [Related]
19. CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease.
Zhu BT
Int J Mol Med; 2004 Mar; 13(3):343-53. PubMed ID: 14767563
[TBL] [Abstract][Full Text] [Related]
20. New hope for mechanism-based treatment of Parkinson's disease.
Bradbury J
Drug Discov Today; 2005 Jan; 10(2):80-1. PubMed ID: 15718152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
